title: Different therapeutic approaches on quality of life in patients with inflammatory bowel disease.
abstract: BACKGROUND
  The chronic nature of inflammatory bowel disease leads to considerable impairment on the health related quality of life (HRQOL). The aims of the present study are to validate the mainland Chinese translation of the Inflammatory Bowel Disease Questionnaire (MCIBDQ), and to evaluate the impact of infliximab treatment on HRQOL in patients with IBD for the first time in China, as compared with other therapies of different levels. Furthermore, the impact of different medical therapies on marriage, employment and economic burden in IBD patients were also evaluated.
  
  
  METHODS
  Consecutive patients who met inclusion/exclusion criteria were investigated with MCIBDQ, SF-36, disease activity index (DAI), marriage, employment and economic burden questionnaires before and after treatment.
  
  
  RESULTS
  MCIBDQ showed significant reliability and validity both in CD and UC patients. The scores of total SF-36, total MCIBDQ and all domains were found significantly increased, while both DAI and health transition on general health scores were found significantly decreased after infliximab treatment (all P < 0.001). Scores of SF-36 and MCIBDQ increased significantly more in infliximab group than non-infliximab group (all P < 0.05). Infliximab treatment was suggested to significantly reduce the negative impact on love (P = 0.037), increase work time (P = 0.016) and ease economic burden (P = 0.048).
  
  
  CONCLUSIONS
  MCIBDQ was demonstrated to be a reliable and valid scale applied in Chinese IBD patients. Infliximab treatment was found to significantly improve HRQOL in IBD patients in comparison with conventional treatments. Negative impact on marriage, employment, and economic status was found in patients with IBD.
authors.forename: Junjie
authors.initials: J
authors.lastname: Xu
authors.forename: Hui
authors.initials: H
authors.lastname: Lin
authors.forename: Xu
authors.initials: X
authors.lastname: Feng
authors.forename: Minyue
authors.initials: M
authors.lastname: Tang
authors.forename: Jun
authors.initials: J
authors.lastname: Shen
authors.forename: Zhihua
authors.initials: Z
authors.lastname: Ran
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D002681:China; D003093:Colitis, Ulcerative / Q000188:drug therapy / Q000191:economics / Q000523:psychology*; D017281:Cost of Illness; D003424:Crohn Disease / Q000188:drug therapy / Q000191:economics / Q000523:psychology*; D004651:Employment; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006304:Health Status; D006801:Humans; D000069285:Infliximab; D008393:Marriage; D011788:Quality of Life; D012074:Remission Induction; D015203:Reproducibility of Results; D011795:Surveys and Questionnaires; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab